Chiome Bioscience Inc

TSE:4583 (Japan)  
円 207.00 (-2.82%) Nov 29
At Loss
P/B:
6.05
Market Cap:
円 12.68B ($ 84.64M)
Enterprise V:
円 11.86B ($ 79.22M)
Volume:
20.42M
Avg Vol (2M):
2.84M
Warning! GuruFocus detected 1 Medium warning sign with 4583. Try a 7-Day Free Trial to check it out.
Trade In:
Volume:
20.42M
Market Cap 円:
12.68B
Market Cap $:
84.64M
At Loss
Avg Vol (2M):
2.84M
Enterprise Value 円:
11.86B
Enterprise Value $:
79.22M
PB Ratio:
6.05
Alerts Website Sources Stock PDF
Dataset
Financial Download GuruFocus Premium Icon Manual of Stocksâ„¢

Business Description

Chiome Bioscience Inc
NAICS : 325412
ISIN : JP3205350006
http://www.chiome.co.jp
Sumitomo Fudosan Nishi-shinjuku Building No.6, 3-12-1, Honmachi, Shibuya-ku, Tokyo, JPN, 151-0071
Compare
Compare
TSE:4564TSE:2385TSE:4594TSE:2342TSE:4591TSE:4570TSE:4576TSE:4584TSE:4896TSE:4596OCSE:NOVO BVRTXREGNASX:CSLSGENXKRX:207940MRNAHKSE:02269XBRU:ARGXBNTX
Traded in other countries / regions
4583.Japan
IPO Date
2011-12-20
Description
Chiome Bioscience Inc is a Japanese based company engaged in the manufacture and sale of antibody drugs through the Autonomous Diversifying Library System. The business activity of the group is operated through Drug Discovery Alliance, Lead Antibody Licensing, and Licensing Out Platform Technology segments. The Drug Discovery Alliance segment partners with pharmaceutical companies to develop and create lead antibody drugs. The Lead Antibody Licensing Out segment is engaged in the production of specific antibodies against antigens and early licensing out to pharmaceutical manufacturers and the Licensing Out Platform Technology segment conducts research and development through the ADLib System. Geographically all the activities are functioned through Japan.

Financial Strength

6/10
Name Current Vs Industry Vs History
Cash-To-Debt 3.78
Equity-to-Asset 0.69
Debt-to-Equity 0.27
Debt-to-EBITDA -0.26
Piotroski F-Score 4/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 5.82
Distress
Grey
Safe
Beneish M-Score -3.29
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Growth Rank

7/10
Name Current Vs Industry Vs History
3-Year Revenue Growth Rate 0.9
3-Year EBITDA Growth Rate 12
3-Year EPS without NRI Growth Rate 11.9
3-Year FCF Growth Rate 17.1
3-Year Book Growth Rate -34.6

Momentum Rank

5/10
Name Current Vs Industry Vs History
5-Day RSI 59.92
9-Day RSI 65.86
14-Day RSI 67.41
6-1 Month Momentum % -8.85
12-1 Month Momentum % -22.56

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 3.29
Quick Ratio 3.17
Cash Ratio 2.55
Days Inventory 81.55
Days Sales Outstanding 45.34
Days Payable 48.13

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -10
Shareholder Yield % -0.99

Profitability Rank

3/10
Name Current Vs Industry Vs History
Gross Margin % 55.28
Operating Margin % -191.9
Net Margin % -190.76
FCF Margin % -182.05
ROE % -96.06
ROA % -65.89
ROIC % -232.74
ROC (Joel Greenblatt) % -458.14
ROCE % -91.19

GF Value Rank

1/10
Name Current Vs Industry Vs History
PS Ratio 10.42
PB Ratio 6.05
Price-to-Tangible-Book 10.9
EV-to-EBIT -10.66
EV-to-EBITDA -10.66
EV-to-Revenue 20.21
EV-to-FCF -4.97
Price-to-Median-PS-Value 0.82
Price-to-Net-Current-Asset-Value 12.49
Price-to-Net-Cash 18.92
Earnings Yield (Greenblatt) % -9.38
FCF Yield % -15.17

Financials

TSE:4583's 30-Y Financials
AAPL
Income Statement Breakdown FY
No Enough Data
AAPL
Balance Sheet Breakdown
No Enough Data
AAPL
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Chiome Bioscience Inc Executives

Details

GF Value: 円121.07

TSE:4583

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil 円) 587.303
EPS (TTM) (円) -21.13
Beta 0.99
Volatility % 111.69
14-Day RSI 67.41
14-Day ATR (円) 20.575612
20-Day SMA (円) 139.2
12-1 Month Momentum % -22.56
52-Week Range (円) 75 - 304
Shares Outstanding (Mil) 61.24

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 4
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Chiome Bioscience Inc Filings

Filing Date Document Date Form
No Filing Data

Chiome Bioscience Inc Stock Events

Financials Calendars
Event Date Price(円)
No Event Data

Chiome Bioscience Inc Frequently Asked Questions

What is Chiome Bioscience Inc(TSE:4583)'s stock price today?
The current price of TSE:4583 is 円207.00. The 52 week high of TSE:4583 is 円304.00 and 52 week low is 円75.00.
When is next earnings date of Chiome Bioscience Inc(TSE:4583)?
The next earnings date of Chiome Bioscience Inc(TSE:4583) is .
Does Chiome Bioscience Inc(TSE:4583) pay dividends? If so, how much?
Chiome Bioscience Inc(TSE:4583) does not pay dividend.

Press Release

Subject Date
No Press Release
Research Tools
All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board
Product
Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文
Education
Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation
Company
About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program
Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey
Follow Us
download GuruFocus on Apple store download GuruFocus on Google Play
Disclaimers
GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.
© 2004-2024 GuruFocus.com, LLC. All Rights Reserved.